舒泰神：BDB-001注射液在抗中性粒细胞胞质抗体相关性血管炎方向临床试验首例已入组

Core Viewpoint - The company Shuyou Shen (300204.SZ) has announced the successful enrollment of the first patient in the Phase III clinical trial for its BDB-001 injection, which targets anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis [2][4]. Group 1 - The clinical trial for BDB-001 is registered under the number CTR20253611 [2][4]. - The enrollment of the first patient has been publicly disclosed on the CDE platform [2][4]. - The company encourages stakeholders to monitor future regular reports and project progress announcements for updates [2][4].